Infliximab (Remicade®) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-alpha). Infliximab neutralizes the biological activity of TNF-alpha by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located onthe outer membranes of T cells and similar immune cells) forms of TNF-alpha, and inhibits or prevents the effective binding of TNF-alpha with its receptors.
Sample Type:Serum and plasma
Detection Range:78-2500ng/ml
Detection Limit:0.78ng/ml
Recovery:1000ng/ml of Infliximab was spiked in 10 lots of human serum. Recovery ranges are from 93-109% with an average recovery of 97%.
Specificity:hIgG1 at 250ng/ml was assayed and exhibited no cross-reactivity or interference
Test Principle:This assay employs the sandwich enzyme immunoassay technique. Anti- Infliximab is coated onto a 96-well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized anti-Infliximab antibody. After washing away any unbound substances, enzyme-linked anti- Infliximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Remicade® (domain residing in Fc portion of the Remicade® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is stopped and the intensity of the color is measured. The color intensity is proportional to the amount of Infliximab present in test samples.
Storage and Stability:Store kit components at -20°C unless specified otherwise. Unopened kit is stable for 6 months after receipt. For maximum recovery of product, centrifuge small tubes on pulse setting prior to opening.
